
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
In order to avoid the complications that can present from a surgical eyebrow lift, a study was conducted to test a nonsurgical, noninvasive eyebrow lift method.






